Vanguard Group’s Taysha Gene Therapies TSHA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $25.2M | Buy |
10,894,127
+2,123,206
| +24% | +$4.9M | ﹤0.01% | 2458 |
|
|
2025
Q1 | $12.2M | Sell |
8,770,921
-135,843
| -2% | -$189K | ﹤0.01% | 2740 |
|
|
2024
Q4 | $15.4M | Buy |
8,906,764
+641,305
| +8% | +$1.11M | ﹤0.01% | 2721 |
|
|
2024
Q3 | $16.6M | Buy |
8,265,459
+1,098,122
| +15% | +$2.21M | ﹤0.01% | 2682 |
|
|
2024
Q2 | $16.1M | Buy |
7,167,337
+1,249,923
| +21% | +$2.8M | ﹤0.01% | 2672 |
|
|
2024
Q1 | $17M | Sell |
5,917,414
-278,153
| -4% | -$798K | ﹤0.01% | 2680 |
|
|
2023
Q4 | $11M | Buy |
6,195,567
+867,703
| +16% | +$1.54M | ﹤0.01% | 2896 |
|
|
2023
Q3 | $16.8M | Buy |
5,327,864
+3,738,616
| +235% | +$11.8M | ﹤0.01% | 2614 |
|
|
2023
Q2 | $1.05M | Buy |
1,589,248
+5,810
| +0.4% | +$3.84K | ﹤0.01% | 3881 |
|
|
2023
Q1 | $1.26M | Buy |
1,583,438
+27,772
| +2% | +$22.2K | ﹤0.01% | 3847 |
|
|
2022
Q4 | $3.52M | Buy |
1,555,666
+484,864
| +45% | +$1.1M | ﹤0.01% | 3454 |
|
|
2022
Q3 | $2.07M | Hold |
1,070,802
| – | – | ﹤0.01% | 3728 |
|
|
2022
Q2 | $3.98M | Buy |
1,070,802
+58,638
| +6% | +$218K | ﹤0.01% | 3497 |
|
|
2022
Q1 | $6.6M | Buy |
1,012,164
+128,517
| +15% | +$838K | ﹤0.01% | 3377 |
|
|
2021
Q4 | $10.3M | Buy |
883,647
+77,929
| +10% | +$908K | ﹤0.01% | 3186 |
|
|
2021
Q3 | $15M | Buy |
805,718
+177,074
| +28% | +$3.3M | ﹤0.01% | 3014 |
|
|
2021
Q2 | $13.3M | Buy |
628,644
+168,396
| +37% | +$3.57M | ﹤0.01% | 3056 |
|
|
2021
Q1 | $9.34M | Sell |
460,248
-4,602
| -1% | -$93.4K | ﹤0.01% | 3183 |
|
|
2020
Q4 | $12.3M | Buy |
464,850
+389,850
| +520% | +$10.3M | ﹤0.01% | 2884 |
|
|
2020
Q3 | $1.68M | Buy |
+75,000
| New | +$1.68M | ﹤0.01% | 3534 |
|